Companies › Citryll
2 active drug programs in 3 registered trials: 3 Phase 2; Immunology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CIT-013 | – | Phase 2 | Rheumatoid Arthritis; Hidradenitis Suppurativa (HS) | Apr 2027 |
| [89Zr]Zr-CIT Radiolabeled monoclonal antibody imaging agent targeting neutrophil extracellular traps (N | NONE | Phase 2 | RA | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06567470 | CIT-013 | Phase 2 | Rheumatoid Arthritis | Immunology | Jul 2026 |
| NCT07147959 | [89Zr]Zr-CIT | Phase 2 | RA | Immunology | Jul 2026 |
| NCT06993233 | CIT-013 | Phase 2 | Hidradenitis Suppurativa (HS) | Immunology | Apr 2027 |
–
Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines OrthoTrophix Resolve Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.